Figure 2: Effects of oral GSH supplementation on levels of GSH in plasma, lymphocytes, and buccal cells after 1 month, 3 months, 6 months, and 7 months of treatment
Collectively, these data highlight a key role of mGSH in maintaining a healthy antioxidant system in both systems and on H 2 O 2 homeostasis
"Bulk Drug Substances Nominated for Use in Compounding Under Section 503A." FDA.gov, April 2026.
Proven alternatives deliver comparable results with established safety: tirzepatide monotherapy produces 15-22% weight loss with FDA approval and extensive clinical data, while CagriSema (cagrilintide + semaglutide) delivers 15-25% weight loss with Phase 3 trial validation and clearer path to medical acceptance
However, its half-life in the bloodstream is remarkably short, around 15 minutes, due to rapid degradation by aminopeptidase enzymes